This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letter to the Editor

Development of Subtle Psychotic Symptoms With Memantine: A Case Report

Edward D. Huey, MD;  Irene H. Dustin, MSN, CRNP; Gerald P. Overman, ParhmD; Nadeem Mirza, MD; and Trey Sunderland, MD

Published: May 15, 2005

Article Abstract

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: Memantine is a medication that has been recentlyapproved in the United States for the treatment of moderateto-severe Alzheimer’s disease. It is a low-to-moderate affinity,noncompetitive N-methyl-D-aspartate (NMDA) antagonist.1The use of other noncompetitive NMDA antagonists such asketamine and phencyclidine is known to produce psychoticsymptoms.2,3‘ ‹

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 66

Quick Links: